To further clarify the clinical relevance of the CypA‐SLC7A11 axis in NSCLC chemoresistance, a cohort using specimens from 30 cases of NSCLC (see details in Table 3) was categorized into the responder or non‐responder group based on the sensitivity to chemotherapy. Here, SLC7A11 is linked to non-small cell lung carcinoma.